• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

Alk+ France cancer poumon joins Lung Cancer Europe

We are very happy that Alk Ros1 France Cancer Poumon has become a member of Lung Cancer Europe (LuCE).Alk+ France […]

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]

Five new members join the Lung Cancer Europe (LuCE) network

We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]

New LuCE Board elected at AGM 2024 in Zagreb

We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last […]

Busy schedule planned for AGM 2024 in Zagreb

Lung Cancer Europe (LuCE) Annual General Meeting and General Assembly The Lung Cancer Europe (LuCE) AGM and General Assembly take […]

BMS Press Release is out now

Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]